Evidence map›Paper›PMID 39444338›Full record

ArticleThe Korean journal of internal medicine2024

Kidney replacement therapy trends in end-stage kidney disease patients in South Korea during the COVID-19 pandemic.

Ah-Young Kim, Min-Jeong Lee, Heejung Choi, Hankil Lee, Inwhee Park

Abstract read
In one paragraph

Article in The Korean journal of internal medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Ah-Young KimCollege of Pharmacy, Ajou University, Suwon, Korea.
Min-Jeong LeeDepartment of Nephrology, Ajou University School of Medicine, Suwon, Korea.
Heejung ChoiDepartment of Nephrology, Ajou University School of Medicine, Suwon, Korea.
Hankil LeeCollege of Pharmacy, Ajou University, Suwon, Korea.
Inwhee ParkDepartment of Nephrology, Ajou University School of Medicine, Suwon, Korea.

Funding

Ministry of Food and Drug Safety 21153MFDS602
6 · The paper itself

Abstract

BACKGROUND/

aimsThe corona virus disease 2019 posed a major risk for end-stage kidney disease (ESKD) cases. Our study aimed to assess changes in kidney replacement therapy (KRT) trends and healthcare access for these patients during the pandemic.

methodsWe retrospectively analyzed nationwide data from July 2017 to June 2022 to assess changes in KRT and ESKD incidence. KRT modalities included peritoneal dialysis (PD), hemodialysis (HD), and kidney transplantation (KT). We utilized the interrupted time series (ITS) method to compare changes in KRT modality before and after the incidence of the COVID-19 pandemic.

resultsESKD incidence remained stable from 2018 to April 2022. The ITS analysis confirmed that the pandemic did not significant impact overall KRT incidence. PD cases decreased (5.7% to 1.3%), while HD cases increased (81.6% to 85%), and KT recipient remained relatively stable (12.7% to 17.3%). The hospitalization and hospital stay decreased in nursing hospital (165.01 days to 147.77 days) and general hospital (61.34 days to 55.58 days) during the pandemic, however, remained unchanged for PD and KT.

conclusionOur findings indicate no significant changes in ESKD incidence in South Korea during the pandemic. However, there were shifts in modality distribution, with decreased PD and increased HD cases. Notably, HD cases showed a significant reduction in hospital admissions and length of stay. The healthcare system demonstrated stability during the pandemic, with minimal disruptions in ESKD care.

Indexed as

COVID-19Kidney Failure, ChronicRenal Replacement TherapyAdultAgedFemaleHumansIncidenceKidney TransplantationMaleMiddle AgedRepublic of KoreaRetrospective StudiesSARS-CoV-2Time FactorsCOVID-19DialysisHemodialysisKidney transplantationPeritoneal dialysis

Identifiers

PMID39444338
PMCPMC11569916

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.